Emerging Robotics Target early adopters in radiotherapy centers seeking to upgrade from legacy systems by engaging hospital procurement teams, medical physics, and chief medical officers with a focus on Galileo 4π's added precision, reduced treatment times, and potential for improved patient outcomes.

510k Path Highlight the proximity to regulatory clearance (510(k)) as a selling point to risk-averse institutions; position Celestial Oncology as a first-mover in disruptive radiotherapy technology once clearance is achieved, prioritizing outreach to trial sites and early access programs.

Clinical Differentiation Emphasize the unique multi-directional beam delivery and automated beam-path optimization as a competitive edge; offer partnerships with academic centers for validation studies and clinical collaborations to accelerate adoption.

Funding & Growth Leverage Series A backing to build credibility with investors, hospital finance committees, and strategic partners; propose financing options or phased procurement to lower upfront CAPEX barriers for small to mid-sized radiotherapy centers.

Strategic Alliances Identify potential collaborations with major medical device distributors, oncology software integrators, and hospital IT security teams familiar with ISO 14971 and cybersecurity requirements to streamline deployment and compliance in clinical settings.